INSULIN
UTILIZATION MANAGEMENT CRITERIA

DRUG CLASS: Insulin

BRAND (generic) NAMES:

<table>
<thead>
<tr>
<th>Rapid-Acting Insulins</th>
<th>Short-Acting Insulins</th>
<th>Intermediate-Acting Insulins</th>
</tr>
</thead>
<tbody>
<tr>
<td>NovoLog (insulin aspart)*</td>
<td>Novolin R*</td>
<td>Novolin N*</td>
</tr>
<tr>
<td>Humalog (insulin lispro)</td>
<td>Humulin R</td>
<td>Humulin N</td>
</tr>
<tr>
<td>Apidra (insulin glulisine)</td>
<td>Humulin R U-500</td>
<td></td>
</tr>
<tr>
<td>Afrezza (insulin human)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NPH-Regular Combinations</th>
<th>NPH-Lispro Combinations</th>
<th>NPH – Novolog Combination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novolin 70/30*</td>
<td>Humalog Mix 75/25</td>
<td>NovoLog Mix 70/30*</td>
</tr>
<tr>
<td>Humulin 70/30</td>
<td>Humalog Mix 50/50</td>
<td></td>
</tr>
</tbody>
</table>

*Preferred insulin products.

FDA-APPROVED INDICATIONS:
Humalog (insulin lispro), NovoLog (insulin aspart), Apidra (insulin glulisine)

- Treatment of patients with Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus for the control of hyperglycemia.

Humulin R, Novolin R
- For the treatment of Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus inadequately managed by diet, exercise, and oral hypoglycemics.
- For the treatment of gestational diabetes or for the treatment of patients with pre-existing diabetes mellitus (Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus) who are now pregnant: for pregnant patients with gestational-onset diabetes not controlled by diet-therapy alone.
- For the treatment of diabetic ketoacidosis.
- For the treatment of hyper-osmolar hyperglycemic state in patients with Type 2 Diabetes Mellitus.

Humulin N, Novolin N
- For the treatment of Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus inadequately managed by diet, exercise, and oral hypoglycemics.
- For the treatment of gestational diabetes or for the treatment of patients with preexisting Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus who are now pregnant.

Novolin 70/30, Humulin 70/30
- For the treatment of Type 1 Diabetes Mellitus or for Type 2 Diabetes Mellitus inadequately managed by diet, exercise, and oral hypoglycemics.
Humalog Mix 75/25, Humalog Mix 50/50
• For the treatment of Type 1 Diabetes Mellitus or for Type 2 Diabetes Mellitus inadequately managed by diet, exercise, and oral hypoglycemics.

NovoLog Mix 70/30
• Improve glycemic control in patients with Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus.

Afrezza
• Improve glycemic control in patients with Diabetes Mellitus.

**COVERAGE AUTHORIZATION CRITERIA**

**Nonpreferred insulin products** may be eligible for coverage when:

1. If the request is for Humulin U-500 then:
   a. The patient is currently receiving Humulin U-500; **OR**
   b. The patient is not currently receiving Humulin U-500 and requires more than 200 units of insulin per day.

2. If the request is for Humalog Mix 50/50 then:
   a. The patient is currently receiving Humalog Mix 50/50 AND the prescriber states the patient is at risk of losing good control if switched to a different insulin; **OR**
   b. The patient is not currently receiving Humalog Mix 50/50 AND the prescriber states that the patient has tried and failed a preferred insulin mix (Novolin 70/30, NovoLog Mix 70/30).

3. If the request is for Afrezza, Apidra, Humalog, Humulin R, Humulin N, Humulin 70/30, and/or Humalog Mix 75/25 then:
   a. The patient has a documented adverse reaction, intolerance or FDA labeled contraindication to preferred insulin (Novolin, NovoLog) products.

**DOSAGE AND ADMINISTRATION:**

Dosing must be individualized. The total daily insulin requirement may vary and is usually between 0.5 and 1.0 unit/kg/day.

**REFERENCES:**

8. Novolin 70/30 (70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection, [rDNA]). Novo Nordisk. March 2013.
11. Humalog Mix 50/50 (50% insulin lispro protamine suspension and 50% insulin lispro injection [rDNA origin]). Eli Lilly and Company. November 2013.